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Abstract
Elderly patients with glioblastoma represent a clinical challenge for neurosurgeons and on-
cologists. The data available on outcomes of patients greater than 80 undergoing resection
is limited. In this study, factors linked to increased survival in patients over the age of 80
were analyzed. A retrospective chart review of all patients over the age of 80 with a new di-
agnosis of glioblastoma and who underwent surgical resection with intent for maximal re-
section were examined. Patients who had only stereotactic biopsies were excluded.
Immunohistochemical expression of oncogenic drivers (p53, EGFR, IDH-1) and a marker of
cell proliferation (Ki-67 index) performed upon routine neuropathological examination were
recorded. Stepwise logistic regression and Kaplan Meier survival curves were plotted to de-
termine correlations to overall survival. Fifty-eight patients fit inclusion criteria with a mean
age of 83 (range 80–93 years). The overall median survival was 4.2 months. There was a
statistically significant correlation between Karnofsky Performance Status (KPS) and over-
all survival (P < 0.05). There was a significantly longer survival among patients undergoing
either radiation alone or radiation and chemotherapy compared to those who underwent no
postoperative adjuvant therapy (p < 0.05). There was also an association between overall
survival and lack of p53 expression (p < 0.001) and lack of EGFR expression (p <0.05). In
this very elderly population, overall survival advantage was conferred to those with higher
preoperative KPS, postoperative adjuvant therapy, and lack of protein expression of EGFR
and p53. These findings may be useful in clinical decision analysis for management of pa-
tients with glioblastoma who are octogenarians, and also validate the critical role of EGFR
and p53 expression in oncogenesis, particularly with advancing age.
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Introduction
The clinical paradigm for the treatment of elderly patients with glioblastoma (GBM) remains
controversial [1–5]. Among all patients, the median survival time after GBM diagnosis remains
15 months with aggressive surgical resection, chemotherapy, and radiation [6]. Elderly patients
often have more medical comorbidities and lower Karnofsky Performance Scales (KPS) than
their younger counterparts. This has led to an increased focus on utility and efficacy of surgical
and medical treatment in geriatric patients, with some studies showing increases in life expec-
tancy with aggressive management [7–12], possibly correlated to a higher extent of resection
[13,14]. What is even less clear is the role of these therapies in patients over the age of 80, as
most studies that evaluate a “geriatric” population report on patients aged 65–80. In this study,
we present what is, to our knowledge, the largest cohort of patients in their 8th decade and
older who have undergone surgical resection for glioblastoma and factors associated with
prolonged survival.
Methods
After approval from the University of Pennsylvania Institutional Review Board, a retrospective
review was conducted of all patients who presented to the Hospital of the University of Penn-
sylvania over the age of 80 with a new diagnosis of glioblastoma between January 1st, 2003 and
December 31st, 2013 and underwent surgical resection. All patients presenting as an index glio-
blastoma resection over the age of 80 were included. Only secondary resections and patients
undergoing biopsy alone were excluded. Patient demographics, including age, sex, race, pre-
senting symptoms, pre and postoperative neurological examinations, KPS, intraoperative and
postoperative complications, tumor location, use of adjuvant chemotherapy and radiation,
immunohistochemical staining of p53 (positive vs negative), epidermal growth factor receptor
(EGFR, positive versus negative), and mutated isocitrate dehydrogenase 1 (IDH1, R132H
(present versus absent), time to progression, and overall survival time were recorded. Gross
total resection was defined as imaging findings consistent with “no residual tumor”, and all
other imaging findings were considered sub-total resections. The Karnofsky Performance Sta-
tus is a validated index that allows for patient classification based on their degree of functional
impairment [15]. A higher KPS is representative of better functioning (e.g. a score of 100 is
considered to be a patient without evidence of any impairment, a score of 10 is a moribund pa-
tient). KPS was assigned retrospectively from the history and physical found in the medical re-
cord of each patient. Multiple stepwise logistic regression was used to perform multivariate
analysis, and Kaplan-Meier survival curves were used to evaluate survival times among groups.
Two-tailed T-tests and Wilcoxon-Rank Sum tests as well as multiple analysis of variance was
used to analyze differences between groups. The P-value was set at 0.05. All statistics were per-
formed using JMP 11.2.1 (SAS Institute, Cary, North Carolina, USA).
Results
Fifty-eight patients with a mean age of 83 (range 80–93) years fit inclusion criteria (Table 1).
The most common comorbidities were hypertension (76%), hyperlipidemia (48%), and coro-
nary artery disease (36%). The majority of patients had a preoperative KPS of 70 (35%) or 80
(53%), together accounting for 88% of all study patients. The median time to diagnosis was one
month from the most common presenting symptom, which was an alteration in mental status
(55%, Table 2). Most tumors were confined to the frontoparietal lobes (69%).
The overall median survival (OS) was 4.2 months (0.2–72 months, Fig 1). There was a statis-
tically significant association between a higher KPS and overall survival (P< 0.05, Table 1, Figs
1 and 2). There was no association between age, race, sex, comorbidities, or radiographic
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tumor characteristics and overall survival. There was no association between KPS and EGFR,
Ki-index, IDH1 or p53 status (p>0.05). Gross total resection was achieved in 21% of patients,
with no significant outcome on survival (Table 3). The rate of overall postoperative thrombotic
event was 10%, and the 30-day readmission rate was 17%. The median intensive care unit
Table 2. Presenting symptoms and tumor characteristics.
N = 58
Presenting Symptom
Seizure 6 (10%)
Headache 17 (28%)
Altered mental status 34 (55%)
Cranial nerve palsy 12 (7%)
Sensorimotor deficit 20 (33%)
Aphasia 16 (27%)
Tumor characteristics
Multifocal 7 (12%)
Eloquent 16 (27%)
Frontoparietal 42 (69%)
Occipital 7 (12%)
Brainstem involvement 1 (2%)
Collosal 5 (9%)
doi:10.1371/journal.pone.0127202.t002
Table 1. Demographics.
Characteristic N = 58 P-value
Age, years 83 (80–93) NS
Male 23 (40%) NS
Race NS
African Descent 8 (14%)
Caucasian 43 (74%)
Other 7 (12%)
Comorbidities NS
Diabetes 15 (26%)
Hypertension 44 (76%)
Coronary artery disease 21 (36%)
Hyperlipidemia 28 (48%)
History of cancer 13 (22%)
PE/DVT 14 (23%)
KPS P < 0.05
60 3 (5%)
70 20 (35%)
80 31 (53%)
90 4 (7%)
Legend: Legend: Values provided as mean (with range) or absolute number with percentage. Student’s t-
tests were utilized to analyze the differences between basic demographics, and multiple analysis of
variance (ANOVA) was used to analyze the differences between multiple groups. PE = pulmonary
embolism. DVT = deep vein thrombosis. KPS = Karnofsky Performance Scale
doi:10.1371/journal.pone.0127202.t001
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length of stay was 1 day and the median overall hospital stay was 6 days, neither was associated
with OS. The most common disposition was inpatient neurorehabilitation (53%). The majority
of patients did not undergo any adjuvant therapy (66%), with 10 undergoing radiation alone,
and 10 undergoing radiation and chemotherapy (17%). There was a significant difference in
survival among these three groups, with a median survival of 96.5, 200, and 351 days for pa-
tients with no adjuvant therapy, radiation alone, and chemoradiation (P<0.05. Fig 3).
There was a statistically significant association between lack of EGFR immunohistochemical
expression and increased survival (p< 0.05, median survival 276 vs. 104 days, Table 4, Fig 4).
There was also an association between lack of p53 immunohistochemical expression and in-
creased survival (p< 0.001, median survival 97 vs. 330, Fig 5). There was no statistical correla-
tion between p53 and EGFR expression, or combined survival benefit between lack of both p53
and EGFR expression (p> 0.05). There were no cases of mutated IDH-1 in this cohort (0/22)
in those patients with available IDH-1 staining. There was no association between the Ki-67
proliferation index and overall survival.
Fig 1. Overall survival curve.
doi:10.1371/journal.pone.0127202.g001
Fig 2. Survival curve by KPS. Legend: KPS = Karnofsky Performance Scale. *Denotes p < 0.05.
doi:10.1371/journal.pone.0127202.g002
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Discussion
The decision to proceed with surgical resection of glioblastoma in an elderly patient requires
an informed understanding of potential outcomes and perioperative morbidity. This can be
particularly challenging in patients who are substantially older than the patient population that
is most commonly reported upon. Often times, “geriatric” patients are referred to as age 65 or
70 “onwards”. However, the practical and clinical features of patients in their late 6th decade
are most likely very different than those of patients in their late 8th decade. Even in the light of
recent studies that reveal that both surgical resection (versus biopsy) and aggressive treatment
with chemoradiation may prolong life in a geriatric population, the decision to proceed with
glioblastoma resection in an octogenarian can be particularly complex. In this study, we exam-
ined outcomes of surgical resection of 58 patients aged 80 and older (range 80–93 years). This
cohort of patients is larger and better characterized than the subset of patients in larger studies
who examine geriatric patients with glioblastoma but define them as aged “65 and over” and al-
lows for a better understanding of factors associated with outcomes after surgical resection in a
very unique population. Additionally, each of the 58 patients underwent “maximal safe resec-
tion” with the intent to remove as much tumor burden as possible without resultant
neurological deficit.
In this population, the majority of patients had at least one medical comorbidity as shown
by the greater than 35% of patients with coronary artery disease and hyperlipidemia, and the
Table 3. Postoperative Profiles.
Characteristics P-value
Resection Status
Gross total resection 12 (21%) NS
Subtotal Resection 40 (69%)
Postoperative Complications
Surgical site infection 1 (2%)
Seizure 5 (9%)
Deep vein thrombosis 5 (9%)
Pulmonary embolism 1 (2%)
30-day readmission 10 (17%)
Adjuvant treatment
No adjuvant therapy 38 (66%)
Radiation only 10 (17%) P < 0.05
Radiation + chemotherapy 10 (17%)
Disposition
ICU length of stay 1 (1–30 days) NS
Hospital length of stay 6 (2–30 days) NS
Home 14 (24%)
Rehab 31 (53%)
SNF 9 (16%)
Hospice 2 (3%)
Inpatient death 2 (3%)
Legend: Values provided as median (with range) or absolute numbers with percentage. Wilcoxon Rank
Sum tests were used to determine differences in overall survival between those who underwent gross total
and subtotal resection, as well as survival differences in the adjuvant treatment group and length of stay
parameters. NS = not significant (p > 0.05). ICU = intensive care unit. SNF = skilled nursing facility.
doi:10.1371/journal.pone.0127202.t003
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76% with hypertension. These factors, along with age itself, were not associated with a decrease
in overall survival. This is likely a reflection of the inherent homogeneity of a patient popula-
tion that has already reached its 8th decade of life, at which time medical comorbidities are very
common and differences in age are less important than their Karnofsky Performance Scale,
consistent with several studies in the elderly GBM population [16,17]. Also consistent with this
literature, KPS was significantly correlated to overall survival [18](Fig 2).
Notably in this study, the expression of the proteins EGFR and p53 had a significant impact
on survival time. Patients who did not have immunohistochemical expression of EGFR and
p53 had a significantly longer median survival time than those with positive expression. In this
study, lack of p53 and EGFR expression were found to be independent predictors of survival.
Lack of co-expression of p53 and EGFR did not confer additional benefit, and expression of
EGFR and p53 were not associated with KPS. The role of p53 in glioma progression is an ongo-
ing discussion, with a working hypothesis that the over-expression of mutated p53 may mark a
Fig 3. Survival curve by adjuvant therapy. * Denotes p < 0.05. Tx = treatment. Rad = radiation.
doi:10.1371/journal.pone.0127202.g003
Table 4. Immunohistochemical staining.
Protein P-value
EGFR (+) 20 (35%)
EGFR (-) 27 (47%) P < 0.05
p53 (+) 27 (47%)
p53 (wt) 4 (14%) P < 0.05
Mutant IDH1 (+) 0 (0%)
Mutant IDH (-) 22 (38%)
Ki index (< 30%) 26 (77%) NS
Ki index (31 to 50%) 5 (15%)
Ki index (>50%) 3 (9%)
Legend: EGFR = epidermal growth factor receptor. IDH1 = isocitrate dehydrogenase. Ki index = Antigen
Ki-67 index. EGFR (+) = positive staining for the epidermal growth factor receptor. EGFR (-) = no staining
for the epidermal growth factor receptor was present. P53 (+) = presence of p53 immunohistochemical
staining. P53 (wt)- wt = wild type. No immunohistochemical p53 staining was found. Total simple size for
EGFR was 47 patients. Total simple size for P53 staining was 31. IDH1 staining was available in 22
patients. Ki index was available in 34 patients.
doi:10.1371/journal.pone.0127202.t004
Glioblastoma in Octogenarians
PLOS ONE | DOI:10.1371/journal.pone.0127202 May 15, 2015 6 / 9
more aggressive tumor biology and that TP53 mutations may participate in progression from
low-grade to a higher grade lesion [19]. EGFR alteration has similarly been implicated, along
with p53, in portending worse overall outcome among patients with primary GBM [20]. The
findings in this study are consistent with previous literature, but also provide a possible prog-
nostic factor in this specific age group. Another potential hypothesis, albeit preliminary, is the
possibility that cell senescence associated genes may be overexpressed and may phenotypically
alter the characteristics of the glioblastoma, resulting in differential survival curves [21], but fu-
ture work may elucidate these mechanisms.
Several other groups have reported that temozolomide and radiation may prolong survival
after glioblastoma resection [7,9,11,22], while others have advocated an abbreviated course of ra-
diation for the very elderly [23]. Our data also shows a significantly increased survival among pa-
tients who underwent either radiation or chemoradiotherapy compared to those with no
postoperative treatment. The link between the utility of adjuvant therapy and overall survival is
often contingent on the ability to differentiate between preoperative survival probabilities and the
benefit that adjuvant therapymay confer. This may support some previous work suggesting prop-
erly selected elderly patients may be eligible for enrollment in chemoradiotherapy trials [24].
Fig 4. EGFR expression and survival. EGFR = epidermal growth factor receptor. * Denotes p < 0.05.
doi:10.1371/journal.pone.0127202.g004
Fig 5. P53 expression and overall survival.Wt = wild type. * Denotes p < 0.05.
doi:10.1371/journal.pone.0127202.g005
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Unlike in several other studies, we did not find extent of resection to be correlated to a higher
overall survival in our cohort [7,13,14]. This is likely due to our strict definition of gross total re-
section as “no residual tumor” noted on post-operative imaging, but also due to our institutional
bias towards “maximal safe resection” in this patient group. This implies a resection that at-
tempts to debulk the majority of tumor burden with minimal possibility of neurological deficit.
In most populations resection of glioblastoma followed by adjuvant therapy is standard of
care. In the elderly and particularly the very elderly, this becomes less clear. In this study as in
others, the preoperative KPS was predictive of overall survival. Based on this, it becomes difficult
to advocate for resection in patients with a KPS of 60. Conversely it is easier to support resection
for patients with a KPS of 90. It is in patients with an intermediate KPS of 70 or 80 in which the
other prognostic factors in this study become useful, including EGFR and p53 status. The ability
to recognize the expression of these proteins as independent variables may provide some insight
into the decision to be more or less aggressive with adjuvant therapy in this population.
There are multiple limitations of this study’s generalizability. First, it is a retrospective co-
hort of a very specific patient population and although the statistical findings were significant
it lacks a prori power analysis necessary to be more definitive in its conclusions. Secondly, p53
and EGFR status in our institution only become standard pathology screening during 2009,
and so data is limited to a shorter time period than the total enrollment period of the study. De-
spite these limitations, we found our conclusions well supported by our available data.
Perhaps most importantly, and not addressed in this study (or most others), are quality of
life indices and their effects on patient perceptions of what is still currently a terminal diagno-
sis, even with maximal care. In one study, it was estimated that patients older than 75 spent
more than ¾ of their remaining life in hospitals [25]. Understanding quality of life after resec-
tion and providing a maximal safe resection are important components of a surgeon’s arma-
mentarium. In this study, we provide two proteins whose expression is associated with
increased survival in a very elderly population. Further studies are necessary to better elucidate
a treatment paradigm for this very specific but challenging patient population.
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